MorphoSys AG Announces Additional Clinical Trial of MOR208

MARTINSRIED / MUNICH, Germany, Dec. 10, 2013 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that the Ohio State University (OSU), Department of Internal Medicine led by Prof. Dr. John Byrd, Director Division of Hematology, initiated an investigator sponsored trial to evaluate the efficacy and safetyof MOR208 in combination with lenalidomide (Revlimid®) in patients with chronic lymphocytic leukemia (CLL). The trial is being conducted by the sponsor investigator Dr. Jennifer Woyach, Assistant Professor of Internal Medicine at the OSU, and is expected to enroll up to 20 treatment naïve and 20 relapsed/refractory CLL patients. The open-label, multi-dose, double-arm trial is entitled "A Phase II Study of MOR00208 in Combination with Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Prolymphocytic Leukemia (PLL) or Patients with Untreated CLL/SLL/PLL". MorphoSys will provide MOR208 drug supply for the study. More information on the trial can be found by searching for MOR208 on www.clinicaltrials.gov.

Help employers find you! Check out all the jobs and post your resume.